ALK inhibition demonstrated dramatic efficacy for our patient who had chemotherapy- and BV-resistant ALK+ ALCL with leukemic presentation, and successfully bridged the patient to HSCT during CR. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.